Mesoblast Limited
General ticker "MEOBF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Mesoblast Limited follows the US Stock Market performance with the rate: 20.3%.
Estimated limits based on current volatility of 0.2%: low 1.91$, high 1.92$
Factors to consider:
- Total employees count: 108 as of 2016
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [0.67$, 1.79$]
- 2026-06-30 to 2027-06-30 estimated range: [0.63$, 1.68$]
Short-term MEOBF quotes
Long-term MEOBF plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $5.90MM | $17.20MM | $122.76MM |
| Operating Expenses | $90.05MM | $79.64MM | $175.11MM |
| Operating Income | $-84.15MM | $-62.44MM | $-52.34MM |
| Non-Operating Income | $-4.00MM | $-39.37MM | $-5.73MM |
| Interest Expense | $20.66MM | $23.32MM | $24.34MM |
| R&D Expense | $25.35MM | $34.81MM | $99.55MM |
| Income(Loss) | $-88.15MM | $-101.81MM | $-58.08MM |
| Taxes | $-0.19MM | $0.33MM | $0.63MM |
| Net Income(Loss)* | $-87.96MM | $-102.14MM | $-58.70MM |
| Stockholders Equity | $480.36MM | $597.44MM | $568.40MM |
| Inventory | $0.00MM | $22.25MM | $28.11MM |
| Assets | $669.15MM | $784.68MM | $773.08MM |
| Operating Cash Flow | $-48.46MM | $-49.95MM | $-43.83MM |
| Capital expenditure | $0.33MM | $0.73MM | $0.90MM |
| Investing Cash Flow | $-0.10MM | $0.12MM | $-1.02MM |
| Financing Cash Flow | $40.25MM | $147.34MM | $-15.33MM |
| Earnings Per Share** | $-0.09 | $-0.08 | $-0.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.